Hoth Therapeutics Candidate Shows Impact On Fat Production And MetabolismThe HT-VA study demonstrated that parenteral GDNF (Glial Cell-Derived Neurotrophic Factor) significantly reduces fat production and enhances fat metabolism at the genetic level, positioning it as a unique therapeutic option for MAFLD and obesity.Hoth Therapeutics is a clinical-stage biopharmaceutical company.The data show statistically significant modulation of genes linked to hepatic fat dynamics, positioning GDNF as a differentiated ...